Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Cancer Res. 2022 Mar 15;82(6):1038–1054. doi: 10.1158/0008-5472.CAN-21-0622

Figure 8: Therapeutic efficacy of ABBV-085 in the PH127 and PH081 OC PDX xenograft model.

Figure 8:

(A) Schematic representation of the early metastatic model of PH127 PDX xenograft. (B) Percent change in tumor area in PH127 PDX early metastatic model following treatments with ABB-085 and control drugs as determined by ultrasound (US) weekly. (C) Graphical analysis of the time required for the detectable tumor engraftment in each mouse from the three treatment cohorts. (D) Schematic representation of PH081 PDX in the pre- and post-treatment models. (E) Percent change in tumor area in the PH081 PDX early metastatic model and in the late metastatic model (F) following treatments with the drugs as determined by ultrasound weekly.